A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

Science

Volumn 278, Issue 5341, 1997, Pages 1309-1312

  Lacronique, Virginie ^a   Boureux, Anthony ^b   Della Valle, Véronique ^a   Poirel, Hélène ^a   Tran Quang, Christine ^b   Mauchauffé, Martine ^a   Berthou, Christian ^c   Lessard, Michel ^c   Berger, Roland ^a   Ghysdael, Jacques ^b   Bernard, Olivier A ^a  

^a INSERM   (France)

^b CNRS   (France)

^c CHU MORVAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; PROTEIN TYROSINE KINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

JANUS;

EID: 15444339209     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.278.5341.1309     Document Type: Article

References (30)

1. T. H. Rabbitts, Nature 371, 143 (1994).
2. O. A. Bernard, S. P. Romana, H. Poirel, R. Berger, Leuk. Lymphoma 23, 459 (1996).
3. T. Golub et al., Biochim. Biophys. Acta 1288, 7 (1996).
4. T. R. Golub, G. F. Barker, M. Lovett, D. G. Gilliland, Cell 77, 307 (1994).
5. S. P. Romana et al., Blood 85, 3662 (1995).
6. M. Baens, P. Peeter, C. Guo, J. Aerssens, P. Marynen, Genome Res. 6, 404 (1996).
7. O. Silvennoinen et al., Proc. Natl. Acad. Sci. U.S.A. 90, 8429 (1993).
8. V. Lacronique et al., data not shown.
9. M. A. Pritchard, E. Baker, D. F. Callen, G. R. Sutherland, A. F. Wilks, Mamm. Genome 3, 36 (1992).
10. PCR experiments were performed starting from 100 ng of randomly primed reverse-transcribed RNA for 35 cycles. The primers used for PCR were B8, B12 (25), P3 (tggaattcTGCAGTGGAGGAGATAAA), and P6 (CCTTGCCAAGTTGCTGTAGA) for JAK2. The specificity of the amplifications was verified by nucleotide sequence analysis.
11. J. N. Ihle, Adv. Cancer Res. 68, 23 (1996).
12. O. Miura et al., Blood 84, 1501 (1994).
13. J. Ihle and I. Kerr, Trends Genet. 11, 69 (1995).
14. Y. Fujitani et al., Oncogene 14, 751 (1997).
15. F. Kohlhuber et al., Mol. Cell. Biol. 17, 695 (1997).
16. C. Jousset et al., EMBO J. 16, 69 (1997).
17. T. Golub et al., Mol. Cell. Biol. 16, 4107 (1996).
18. P. Peeters et al., Blood 90, 2535 (1997).
19. J. Feng et al., Mol. Cell. Biol. 17, 2497 (1997).
20. 4 cells per well). The number of wells showing proliferating cells in either the absence or presence of IL-3 was scored after 1 week in culture.
21. N. Meydan et al., Nature 379, 645 (1996).
22. H. Luo, W. Hanratty, C. Dearotf, EMBO J. 14, 1412 (1995).
23. H. Luo et al., Mol. Cell. Biol. 17, 1562 (1997).
24. D. A. Harrison, R. Binari, T. Stines Nahreini, M. Gilman, N. Perrimon, EMBO J. 14, 2857 (1995).
25. S. P. Romana et al., Blood 86, 4263 (1995).
26. The cDNA from patient 2 (an atypical chronic myelogenous leukemia case in transformation) was amplified with the TEL primer ATGCACCCTCTGATCCTGAACC and the JAK2 primer TGGTGAGGTTGGTACATCAG. The cDNA from patient 3 (a precursor B cell ALL case) was amplified with the TEL primer TTCCACCCTGGAAACTCTATA and the JAK2 primer AAGGTTTGCTAATTCTGCCCACTTTGGTGC. PCR products were sequenced on an ALF sequencer.
27. H. Poirel et al., Oncogene 14, 349 (1997).
28. J. Morgenstern and H. Land, Nucleic Acids Res. 18, 3587 (1990).
29. C. Pallard et al., EMBO J. 14, 2847 (1995).
30. We thank M. Le Coniat for FISH experiments, H. Beug for the murine Jak2 cDNA, P. Mayeux for helpful hints, P. Peeters and P. Marynen for sharing unpublished data, and S. Gisselborecht and G. Calothy for critical reading of the manuscript. Supported by the Association pour la Recherche sur le Cancer (V.L. and A.B.), the Ligue Nationale Contre le Cancer (C.T.Q.), and funds from INSERM, CNRS, Institut Curie, Association pour la Recherche sur le Cancer, Ligue Nationale Contre le Cancer, Ligue Départementale Contre le Cancer (Comité de Paris), and the Biomed Programme of the European Community (contract BMH4-CT96-1355).